Back to news

SciSparc Jumps as Investors React to NeuroThera’s Quantum-Analysis Update

Investivoq PriceTracker

SciSparc Ltd. (SPRC) is up 16.5% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be investor interest in SciSparc’s recent update from subsidiary NeuroThera Labs and its CliniQuantum unit, which highlighted faster quantum-enabled analysis of large clinical gene datasets. In a thinly traded micro-cap stock, that kind of technology-focused announcement can quickly spark speculative buying even without an immediate revenue impact.

Details:

  • SciSparc disclosed on October 7 that CliniQuantum used a GPU-accelerated quantum-simulation platform to analyze more than 7.3 billion possible three-gene combinations and said the run was about 16.8 times faster than a CPU-only setup.
  • The company said the work was a computational benchmark and did not establish clinical validity or immediate commercial utility, but the release still broadened the story around its pipeline beyond cannabinoid drug development.
  • An earlier September update also expanded NeuroThera’s U.S. patent portfolio through work on combinations involving LSD, ketamine and ibogaine, which may have helped keep speculative attention on the name.
  • Fundamentals remain weak: in its latest interim filing, SciSparc reported $284 thousand of six-month revenue, a $6.1 million net loss, and said its cash position was not sufficient to fund operations for at least the next year, raising substantial doubt about its ability to continue as a going concern.

    • Sources:

    SEC, GlobeNewswire, Investing.com

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $SPRC Insider Trading Activity

    SPRC Insider Trades

    $SPRC insiders have traded $SPRC stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

    Here’s a breakdown of recent trading of $SPRC stock by insiders over the last 6 months:

    • ITSCHAK SHREM sold 462 shares for an estimated $4,620

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive SPRC Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $SPRC Hedge Fund Activity

    We have seen 7 institutional investors add shares of $SPRC stock to their portfolio, and 1 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • HRT FINANCIAL LP added 21,235 shares (+inf%) to their portfolio in Q2 2026, for an estimated $117,217
    • JANE STREET GROUP, LLC added 16,496 shares (+inf%) to their portfolio in Q2 2026, for an estimated $91,057
    • UBS GROUP AG added 1,372 shares (+43.6%) to their portfolio in Q2 2026, for an estimated $7,573
    • JPMORGAN CHASE & CO added 211 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,164
    • MORGAN STANLEY added 200 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,104
    • STRATEGIC INVESTMENT SOLUTIONS, INC. /IL removed 133 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $734
    • ROYAL BANK OF CANADA added 32 shares (+inf%) to their portfolio in Q2 2026, for an estimated $176

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.